Natriuretic Peptides Inhibit DNA Synthesis in Cardiac Fibroblasts

  • David G. Gardner
    From the Metabolic Research Unit and Department of Medicine, University of California at San Francisco.
  • Li Cao
    From the Metabolic Research Unit and Department of Medicine, University of California at San Francisco.

書誌事項

公開日
1995-02
DOI
  • 10.1161/01.hyp.25.2.227
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:italic>Abstract</jats:italic> We have examined the effects of the natriuretic peptides on DNA synthesis in primary cultures of neonatal rat cardiac fibroblasts. Binding analysis using <jats:sup>125</jats:sup> I-labeled atrial natriuretic peptide identified a single class of high-affinity binding sites ( <jats:italic>K</jats:italic> <jats:sub>d</jats:sub> =0.03±0.01 nmol/L) in these cells. Of these sites, 80% appear to be of the natriuretic peptide C receptor subtype, with the remainder being A and B receptor subtypes. Northern blot analysis confirmed the presence of all three natriuretic peptide receptors in these cells. Atrial natriuretic peptide (10 <jats:sup>−7</jats:sup> mol/L) effected a modest but consistent reduction in both agonist- and stretch-stimulated [ <jats:sup>3</jats:sup> H]thymidine incorporation (17% to 41%). Moreover, brain natriuretic peptide (10 <jats:sup>−7</jats:sup> mol/L), C-type natriuretic peptide (10 <jats:sup>−7</jats:sup> mol/L), and des-[Gln <jats:sup>18</jats:sup> ,Ser <jats:sup>19</jats:sup> ,Gly <jats:sup>20</jats:sup> ,Leu <jats:sup>21</jats:sup> ,Gly <jats:sup>22</jats:sup> ]-ANF 4-23-NH <jats:sub>2</jats:sub> (10 <jats:sup>−7</jats:sup> to 10 <jats:sup>−6</jats:sup> mol/L) all proved capable of antagonizing growth factor–dependent [ <jats:sup>3</jats:sup> H]thymidine incorporation (the inhibition ranged from 14% to 28%) and cell proliferation, suggesting that all three natriuretic peptide receptor subtypes are involved in the regulation of mitogenesis in these cultures. The inhibition by atrial natriuretic peptide was amplified by cotreatment with phosphodiesterase inhibitors. Similar reduction in [ <jats:sup>3</jats:sup> H]thymidine incorporation was seen after treatment with 8-bromo-cGMP (10 <jats:sup>−4</jats:sup> to 10 <jats:sup>−3</jats:sup> mol/L) or nitroprusside (10 <jats:sup>−4</jats:sup> to 10 <jats:sup>−3</jats:sup> mol/L). These results suggest an important paracrine role for the natriuretic peptides in regulating fibroblast growth during cardiac hypertrophy. </jats:p>

収録刊行物

  • Hypertension

    Hypertension 25 (2), 227-234, 1995-02

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (8)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ